A Phase Ib/II Study of AZD2171 in Combination With Daily Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma Not Taking Enzyme-Inducing Anti-Epileptic Drugs

Trial Profile

A Phase Ib/II Study of AZD2171 in Combination With Daily Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma Not Taking Enzyme-Inducing Anti-Epileptic Drugs

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 May 2017

At a glance

  • Drugs Cediranib (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 03 Feb 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2017, as reported by ClinicalTrials.gov.
    • 11 Mar 2013 Planned number of patients changed from 80 to 40 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top